| PEB0248 | Polyherbacy among people living with HIV in resource limited settings: Implication for drug-herb interactions | E-poster | B34 |
| PEB0249 | Outcomes of methadone maintenance therapy combined with ripivirine/efavirenz in treatment-naive HIV-infected patients: A pilot study | E-poster | B34 |
| PEB0250 | Inflammation, immune activation and microbial translocation in persons living with four-class drug resistant HIV: Data from the PRESTIGIO registry | E-poster | B35 |
| PEB0251 | Viral C-Terminal region P7 ' P6gag Gag polymorphisms and protease drug resistance mutations profile in HIV-1 infected patients failing protease Inhibitors combination therapy | E-poster | B35 |
| PEB0252 | Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) beyond the presence of the M184V mutation | E-poster | B35 |
| PEB0253 | High efficacy after switching to Integrase Strand Transfer Inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure with or without resistance | E-poster | B35 |
| PEB0254 | Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies | E-poster | B35 |
| PEB0255 | NRTI mutations scenario in Europe: How they have changed and their implication in HIV prevention and therapy | E-poster | B35 |
| PEB0256 | Durability of second-line anti-retroviral therapy and predictors of viral rebound among HIV patients on second-line ART in an HIV specialist clinic in Uganda: A 10-year retrospective cohort | E-poster | B35 |
| PEB0257 | Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 | E-poster | B35 |